Investor
Telehealth company Caregility, hybrid cancer care company Daymark Health and virtual care company AmplifyMD also garnered funding.
The company will use the funds to expand Dreem Health, scale nationwide and advance its FDA-cleared sleep apnea technology.
The Series D funding brings the company’s total raise to $275 million and its valuation to more than $1 billion.
The integrated platform will combine patient engagement, care access, provider data management, price transparency and payment tools.
The company stated Capital Rx will still operate as its pharmacy benefits manager brand under Judi Health.
At an event in Washington, D.C., on Monday, DiMe released a thesis with what it says are four impact areas that are vital to pursue in digital medicine in the next five years.
The company will use the funds to expand nationally, enhance its technology platform and advance clinical innovation.
The funds will be used to expand its direct-to-consumer services and grow partnerships with payers and health systems.
The round follows a $200 million seed raise earlier this year.
The funding round comes one month after the company announced it secured a $35 million investment.